UiPath (NYSE:PATH) Trading 1.4% Higher

UiPath Inc. (NYSE:PATH) traded up 1.4% on Thursday . The stock traded as high as $12.19 and last traded at $12.10. 1,809,742 shares traded hands during trading, a decline of 82% from the average session volume of 9,851,194 shares. The stock had previously closed at $11.93.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Bank of America reissued a “neutral” rating and set a $16.00 target price (down previously from $30.00) on shares of UiPath in a research report on Thursday, May 30th. DA Davidson cut their target price on UiPath from $24.00 to $13.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. Barclays cut their target price on UiPath from $25.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 30th. TD Cowen reissued a “hold” rating and set a $17.00 target price (down previously from $28.00) on shares of UiPath in a research report on Thursday, May 30th. Finally, Mizuho cut their price objective on UiPath from $25.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. Sixteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, UiPath currently has a consensus rating of “Hold” and a consensus price target of $18.06.

UiPath Trading Up 1.3 %

The firm has a market cap of $7.08 billion, a P/E ratio of -77.31 and a beta of 0.86. The business has a 50-day moving average price of $13.30 and a 200-day moving average price of $19.11.

UiPath (NYSE:PATH) last announced its quarterly earnings data on Wednesday, May 29th. The healthcare company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. The firm had revenue of $335.11 million for the quarter, compared to the consensus estimate of $332.84 million. On average, equities analysts anticipate that UiPath Inc. will post -0.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $19.79, for a total transaction of $791,600.00. Following the transaction, the chief financial officer now owns 946,848 shares in the company, valued at $18,738,121.92. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 22.37% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On UiPath

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PATH. Mark Sheptoff Financial Planning LLC purchased a new stake in UiPath in the fourth quarter valued at $25,000. HighMark Wealth Management LLC acquired a new stake in shares of UiPath in the fourth quarter valued at $27,000. ORG Partners LLC raised its holdings in shares of UiPath by 875.6% in the 1st quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after buying an additional 1,112 shares during the period. Cypress Capital Management LLC WY purchased a new stake in shares of UiPath in the 4th quarter valued at $29,000. Finally, GAMMA Investing LLC purchased a new stake in shares of UiPath in the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 62.50% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.